Harbour Biomed announced a long‑term strategic collaboration with Yantai Lannacheng Biotechnology to advance next‑generation radionuclide‑drug conjugates for cancer therapy. The alliance combines Harbour Biomed’s biologics discovery capabilities with Lannacheng’s radiochemistry and manufacturing experience to accelerate development of targeted radiopharmaceuticals. The agreement aims to push radionuclide‑drug conjugates into new tumour types and to optimize linker‑payload chemistry and targeting moieties. Companies expect preclinical programs and IND‑enabling work to move forward under the collaboration and flagged potential clinical partnerships contingent on early translational success. The deal reflects growing industry interest in targeted radiotherapeutics as an extension of antibody–drug conjugate and peptide‑receptor radionuclide therapy approaches.